Track topics on Twitter Track topics that are important to you
In a time characterised by globalisation, the international dimension of Bial is playing an ever greater role in the group’s strategic objectives. Being part of the global market and responding to the needs of the people in an ever larger number of world regions is an essential part of Bial’s commitment to Society.
Bial is today an International Pharmaceutical Group. Our products are to be found in pharmacies in nearly 30 countries in 4 continents: Europe, America, Africa and Asia. Whether in Spain or in the Dominican Republic, Portugal or Mozambique, Cyprus, Senegal or Ecuador, the members of the Bial Group and its representatives always strive to serve and satisfy health professionals and the general public. Some of the group companies are: Laboratórios Bial, Medibial, Bialfar, Bialport, Bial Aristegui, Medimport and Medangol.
Phone: 351 22 986 6100
Fax: 351 22 986 6190
Neurocrine Biosciences Inc. licensed exclusive North American development and commercialization rights to Bial-Portela & CA SA's Ongentys (opicapone), in Phase III in the US for Parkinson's disease (P...
Bial and its licensee Eisai have reported positive real-life data of Zebinix (eslicarbazepine acetate) from the Euro-Esli study in patients with partial-onset seizures (POS).
Bial and Eisai have reported a positive outcome from a Phase II clinical trial (Study 208) of Zebinix (eslicarbazepine acetate) in children with focal-onset epilepsy.
Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset epilepsy in adults, as part of a post-market study of mor...
Portuguese pharma firm BIAL and Japan’s Eisai have announced data from a Phase II study which showed…
Precis A Phase I first in human clinical trial on healthy volunteers, sponsored by Portuguese pharmaceutical company Bial, went horribly wrong in early January 2016, leaving one volunteer dead and fiv...
Bial et Eisai présentent aujourd'hui les données confirmant l'efficacité et la tolérance de Zebinix ® (acétate d'eslicarbazépine) dans la pratique clinique quotidienne, données qui viennent...
BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food ef...
Drainage waters at the metal mining areas often have low pH and high content of dissolved metals due to oxidation of sulfide minerals. Extreme conditions limit microbial diversity in- such ecosystems....
Founded in 1924, Bial is an international pharmaceutical group with products available in over 30 countries throughout four continents. BIAL is the largest Portuguese pharmaceutical company and is...
In a time characterised by globalisation, the international dimension of Bial is playing an ever greater role in the group’s strategic objectives. Being part of the global market and responding to t...
We have published hundreds of BIAL news stories on BioPortfolio along with dozens of BIAL Clinical Trials and PubMed Articles about BIAL for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BIAL Companies in our database. You can also find out about relevant BIAL Drugs and Medications on this site too.
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...